BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Jul 21, 2025 • 9min
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a oral therapy that doesn't require titration and hasn't shown GI tolerability side effects.
Jul 17, 2025 • 25min
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.
Jul 16, 2025 • 31min
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape based on this data. Plus, commentary on CMC, business development, oral therapies, and more.
Jul 16, 2025 • 12min
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is different than others in the field. Plus, the work his team is doing on cyclic peptides in their lab at University of Southampton.
Jul 15, 2025 • 15min
Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC
Co-Founder and CEO Simon Kerry discusses being in Southampton, and why he belives the 'Microcycle' platform beats screening in traditional well plates for discovery work. Curve currently has cash on hand to take at least one program into the clinic.
Jul 11, 2025 • 32min
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and albumin. He compares and contrasts it to key competitor BIMZELX and describes what the company is hoping to see in the trial readout. Plus, commercial plans, pipeline, and more.
Jul 7, 2025 • 22min
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the need for an oral therapy and the company's commercial strategy now that the approval is in hand.
Jun 30, 2025 • 16min
AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery
Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome over time is a more realistic way of discovering small molecules that will work rather than via protein-target structure models. He also discovers how the company is leveraging this for its focus on aging conditions and longevity.
Jun 27, 2025 • 14min
Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more
She gives a scenario analysis in the event that FDA asked Capricor for more data rather than approving the therapy by its August 31st decision date. Plus, commentary on ProQR, Korro Bio, Wave, Crinetics, Dyne, Rezolute, Larimar, and Aldeyra.
Jun 27, 2025 • 21min
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.
